Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sentinel Lymph Node Biopsy in Ductal Cancer in Situ or Unclear Lesions of the Breast and How to Not do it. An Open-label, Phase 3, Randomised Controlled Trial. (SentiNot 2.0).

NCT04722692 is registered in ClinicalTrials.gov with Uppsala University as lead sponsor.

NCT NCT04722692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04722692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sentinel Lymph Node Biopsy in Ductal Cancer in Situ or Unclear Lesions of the Breast and How to Not do it. An Open-label, Phase 3, Randomised Controlled Trial. (SentiNot 2.0).
Lead sponsor
Uppsala University
Phase
Phase 3
Overall status
Recruiting
Start date
March 1, 2020
Completion date
December 30, 2027
Enrollment
500 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms, dcis, sentinel lymph node